Xilio Therapeutics, Inc. (XLO) Reports 26% Response in Colon Cancer Drug Trial

Xilio Therapeutics, Inc. (NASDAQ:XLO) announced promising updated Phase 2 results for its investigational therapy vilastobart, combined with atezolizumab, in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases.

The combination achieved a preliminary objective response rate of 26%, with deep and durable responses lasting up to 37 weeks. These responses were marked by significant reductions in tumor biomarkers and notable improvements in clinical symptoms.

A healthcare professional working on a computer terminal with a patient in the background.

Importantly, Xilio Therapeutics, Inc. (NASDAQ:XLO) highlighted that a patient with liver metastasis from an earlier trial phase remains on treatment after more than 14 months, emphasizing the potential durability of the response. The safety profile of the vilastobart-atezolizumab combination remained favorable, with a low incidence of immune-related adverse events such as colitis, and only 5% of patients discontinued due to side effects. Most adverse events were mild or manageable.

These findings, presented at the 2025 ASCO Annual Meeting, underscore the potential of vilastobart as a new immunotherapy option for MSS CRC, which is a cancer type historically resistant to immunotherapy and lacking effective treatments, especially for patients without liver metastases.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.